A Phase 3 interventional study of fluticasone furoate/vilanterol and fluticasone furoate in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 1,621 sites in 44 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.
Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one has the largest enrollment, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 1st registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:
Western University, Canada · Sites in Canada
Ages 50–85
National Institute of Respiratory Diseases, Mexico · Sites in Mexico
Ages 35–85 · Women only
By country, each count listing its studies:
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16,568 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 229 across the 25 interventional studies. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 25 have an industry lead sponsor. The 5 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline: 7 open now, 8 under way, 5 of them phase 3. Of 264 finished, 141 (53%) have results posted.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one has the largest enrollment of the 236 interventional ones that give a count, is one of 26 that started in 2011, is one of 65 in phase 3, and was the 102nd registered.
GlaxoSmithKline’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2000.
1 of the studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07192016Western University, Canada129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 276 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
Despite a potential link between the pathogenetic mechanisms involved in Chronic Obstructive Pulmonary Disease (COPD) and atherosclerotic cardiovascular disease, there are no currently approved therapies for patients with COPD that have clearly shown an additional beneficial effect in patients with cardiovascular comorbidities. The TOwards a Revolution in COPD Health (TORCH) study assessed the impact of the inhaled corticosteroid (ICS) fluticasone propionate (FP) in combination with the long-acting beta agonist (LABA), salmeterol (SAL), in reducing all-cause mortality. TORCH demonstrated a 17.5% reduction on all-cause mortality with salmeterol-fluticasone propionate combination (SFC) compared with placebo (HR=0.825, 95% CI (0.681, 1.002), p=0.052) in the entire COPD population with disease severity form moderate to very severe. A post hoc analysis of the data restricted to those subjects with an forced expiratory volume in 1 second (FEV1) >=50% predicted with an apparent history of cardiovascular co-morbidities (defined as use at baseline of beta-blockers, angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), HMG CoA reductase inhibitors (i.e. statins) or a prior MI recorded at baseline) demonstrated a 49% reduction in the risk of dying within 96 weeks for the comparison of SFC with placebo. These post hoc data suggest the possibility of an ICS/LABA combination product to be of substantial benefit in COPD subjects with less severe airflow obstruction yet with increased cardiovascular risk.
The mechanism by which SFC appears to be associated with a greater reduction in mortality in these less severe COPD subjects with concomitant cardiovascular comorbidities is speculative at present, but could potentially in part be related to a lessening of the degree of inflammation in the systemic circulation, potential plaque stabilization and/or amelioration of arterial stiffness.
ICS/LABA combinations that are currently available require twice daily administration. A once daily ICS/LABA combination has the potential to improve patient compliance and as a result, overall disease management.
The purpose of this study is to prospectively evaluate the effect of the once daily ICS/LABA combination Fluticasone Furoate (FF)/Vilanterol (VI) on survival in subjects with moderate COPD (>=50 and =\<70 % predicted FEV1 ) and a history of, or at increased risk for cardiovascular disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with a measured post-albuterol/salbutamol (FEV1)/(forced vital capacity)FVC ratio of \<=0.70 at Screening (Visit 1).
Subjects with a measured post-albuterol/salbutamol FEV1 >=50 and \<=70% of predicted normal values calculated using NHANES III reference equations [Hankinson, 1999; Hankinson, 2010] at Screening (Visit 1).
Post-bronchodilator spirometry will be performed approximately 15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via a metered dose inhaler (MDI )with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated.
For patients >= 40 years of age: any one of the following:
Established (i.e. by clinical signs or imaging studies) coronary artery disease (CAD) Established (i.e. by clinical signs or imaging studies) peripheral vascular disease (PVD) Previous stroke Previous MI Diabetes mellitus with target organ disease OR
For patients >=60 years of age: any 2 of the following:
Being treated for hypercholesterolemia Being treated for hypertension Being treated for diabetes mellitus Being treated for peripheral vascular disease
Exclusion Criteria:
Medication No use within the following time intervals prior to Screening or thereafter at any time during the study (unless otherwise specified) Inhaled Long acting beta-agonists (LABA) 48 hours ICS/LABA combination products 48 hours Inhaled corticosteroids 48 hours Tiotropium 1 week Systemic, Oral, parenteral, intra-articular corticosteroids 30 days (oral and systemic corticosteroids may be used to treat COPD exacerbations during the study) Cytochrome P450 3A4 strong inhibitors including but not limited to antiretrovirals (protease inhibitors) (e.g.Indinavir, Nelfinavir, Ritonavir, Saquinavir); Imidazole and Triazole anti-fungals (e.g. Ketaconazole, Itraconazole); Clarithromycin, Telithromycin, Amiodarone, and Nefazodone 6 weeks Grapefruit is allowed up to Visit 1, then limited to no more than one glass of grapefruit juice (250 mL/ 8 ounces) or one grapefruit per day Any other drug 30 days or 5 half lives whichever is longer.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination of both products in one inhaler
Drug: fluticasone furoate/vilanterol
comparator of individual component
Drug: fluticasone furoate
comparator of individual component
Drug: vilanterol
once daily via inhaler
Other: Placebo
Drug pages: Fluticasone furoate · Vilanterol
100/25mcg given once daily via novel dry powder inhaler
100mcg given once daily via novel dry powder inhaler
25mcg given once daily via novel dry powder inhaler
placebo comparator once daily via novel dry powder inhaler
Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date
Death from any cause: which occurred from the day of starting IP until the Commone End Date (CED). Common End Date (CED) is the study end date that was pre determined where approximately 1000 deaths would have occurred in the Intent-toTreat Efficacy (ITT-E) Population. Only deaths which occurred on or before the CED were used for the primary analysis. Those who had not died by CED, but who were known to be alive on or after the CED, were censored at the CED. Cox Proportional Hazards (PH) Model was adjusted for age, and gender, including all 4 arms. A hazard ratio of less than 1 indicates a lower death rate versus placebo or other arm. ITT-E Population consisted of all participants in the Safety Population (i.e. randomized to IP and who received at least one dose of IP), with the exception of those recruited at sites that were closed.
Time frame: From the date of randomization until date of death due to any cause (average of 2 study years)
Decline in Forced Expiratory Volume in 1 Second (FEV1)
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The effect of treatment on decline of post bronchodilator FEV1 recorded during the treatment period was analyzed using a particular form of a mixed effect model - a random coefficients model. FEV1 was fitted as the response variable with treatment group, age, gender, baseline FEV1 and time on treatment as fixed effects. Time on treatment was treated as a continuous variable. This model allowed for an initial increase in FEV1, but then tested the difference in slopes from the first post-baseline measurement which was at 3 months. A negative slope indicates a decline. A positive treatment difference indicates a slower rate of decline vs Placebo or Component. Only participants with at least one on-treatment post-bronchodilator FEV1 measurement were analyzed.
Time frame: From start date of IP until IP stop date + 1 (assessed up to 4 years)
Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date
On-treatment CV composite event is comprised of the first event that is adjudicated as on-treatment CV death, myocardial infarction, stroke, unstable angina, or transient ischemic attack experienced by a participant. The events that occurred no more than 7 days after the participants last dose of IP are considered as on-treatment adverse events. Common end date is the study end date where approximately 1000 deaths would have occurred in the ITT-E Population. Cox PH Model was used to assess time to first on-treatment CV composite event. Cox PH Model was adjusted for age, gender and indicators of ischemic and vascular disease, including all four treatment arms. A hazard ratio less than 1 indicates a lower risk of a first CV event rate versus placebo or any arm.
Time frame: From the start of IP to first on treatment CV event till 7 days after the last dose of IP (average of 2 study years)
This study was conducted at 1373 sites. The study employed an event-driven design and was to conclude when approximately 1000 reports of a primary outcome event of death were received. The study consisted of a 4-10 day run-in period, variable treatment period until the required number of events was achieved, and 1 week follow-up period.
| Milestone | Placebo | Fluticasone Furoate 100 µg | Vilanterol 25 µg | Fluticasone Furoate/Vilanterol 100/25 µg |
|---|---|---|---|---|
| Started | 4131 | 4157 | 4140 | 4140 |
| Completed | 2881 | 3044 | 3052 | 3146 |
| Not completed | 1250 | 1113 | 1088 | 994 |
| Withdrew: Adverse event | 395 | 365 | 372 | 333 |
| Withdrew: Lack of efficacy | 98 | 90 | 65 | 46 |
| Withdrew: Protocol violation | 37 | 44 | 46 | 44 |
| Withdrew: Met protocol-defined stopping critera | 3 | 4 | 2 | 11 |
| Withdrew: Study closed/terminated | 7 | 6 | 9 | 9 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 53 | 64 | 62 | 48 |
| Withdrew: Decision by participant or proxy | 643 | 527 | 515 | 492 |
| Withdrew: Sponsor terminated study treatment | 1 | 1 | 0 | 1 |
| Withdrew: Investigator site closed | 12 | 11 | 15 | 10 |
| Withdrew: Missing | 1 | 1 | 1 | 0 |
Death from any cause: which occurred from the day of starting IP until the Commone End Date (CED). Common End Date (CED) is the study end date that was pre determined where approximately 1000 deaths would have occurred in the Intent-toTreat Efficacy (ITT-E) Population. Only deaths which occurred on or before the CED were used for the primary analysis. Those who had not died by CED, but who were known to be alive on or after the CED, were censored at the CED. Cox Proportional Hazards (PH) Model was adjusted for age, and gender, including all 4 arms. A hazard ratio of less than 1 indicates a lower death rate versus placebo or other arm. ITT-E Population consisted of all participants in the Safety Population (i.e. randomized to IP and who received at least one dose of IP), with the exception of those recruited at sites that were closed.
| Participants | Placebo | Fluticasone Furoate 100 µg | Vilanterol 25 µg | Fluticasone Furoate/Vilanterol 100/25 µg |
|---|---|---|---|---|
| Dead | 275 | 251 | 265 | 246 |
| Alive | 3832 | 3884 | 3853 | 3874 |
| Unknown | 4 | 0 | 0 | 1 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The effect of treatment on decline of post bronchodilator FEV1 recorded during the treatment period was analyzed using a particular form of a mixed effect model - a random coefficients model. FEV1 was fitted as the response variable with treatment group, age, gender, baseline FEV1 and time on treatment as fixed effects. Time on treatment was treated as a continuous variable. This model allowed for an initial increase in FEV1, but then tested the difference in slopes from the first post-baseline measurement which was at 3 months. A negative slope indicates a decline. A positive treatment difference indicates a slower rate of decline vs Placebo or Component. Only participants with at least one on-treatment post-bronchodilator FEV1 measurement were analyzed.
| milliliter/year | Placebo | Fluticasone Furoate 100 µg | Vilanterol 25 µg | Fluticasone Furoate/Vilanterol 100/25 µg |
|---|---|---|---|---|
| Decline in Forced Expiratory Volume in 1 Second (FEV1) | -46 ± 2.5 | -38 ± 2.4 | -47 ± 2.4 | -38 ± 2.4 |
On-treatment CV composite event is comprised of the first event that is adjudicated as on-treatment CV death, myocardial infarction, stroke, unstable angina, or transient ischemic attack experienced by a participant. The events that occurred no more than 7 days after the participants last dose of IP are considered as on-treatment adverse events. Common end date is the study end date where approximately 1000 deaths would have occurred in the ITT-E Population. Cox PH Model was used to assess time to first on-treatment CV composite event. Cox PH Model was adjusted for age, gender and indicators of ischemic and vascular disease, including all four treatment arms. A hazard ratio less than 1 indicates a lower risk of a first CV event rate versus placebo or any arm.
| Participants | Placebo | Fluticasone Furoate 100 µg | Vilanterol 25 µg | Fluticasone Furoate/Vilanterol 100/25 µg |
|---|---|---|---|---|
| Had CV composite event | 173 | 161 | 180 | 174 |
| No CV composite event | 3938 | 3974 | 3938 | 3947 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of IP until IP discontinuation + 1 day (average of 2 study years).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 918/4,131 (22.2%) | 1,862/4,131 (45.1%) |
| Fluticasone Furoate 100 µg | — | 929/4,157 (22.3%) | 1,941/4,157 (46.7%) |
| Vilanterol 25 µg | — | 972/4,140 (23.5%) | 1,827/4,140 (44.1%) |
| Fluticasone Furoate/Vilanterol 100/25 µg | — | 961/4,140 (23.2%) | 1,761/4,140 (42.5%) |
| Event | Placebo | Fluticasone Furoate 100 µg | Vilanterol 25 µg | Fluticasone Furoate/Vilanterol 100/25 µg |
|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 262/4131 | 214/4157 | 245/4140 | 189/4140 |
| PneumoniaInfections and infestations | 113/4131 | 121/4157 | 90/4140 | 123/4140 |
| Atrial fibrillationCardiac disorders | 31/4131 | 22/4157 | 30/4140 | 32/4140 |
| Myocardial infarctionCardiac disorders | 24/4131 | 32/4157 | 26/4140 | 24/4140 |
| Cardiac failure congestiveCardiac disorders | 26/4131 | 26/4157 | 21/4140 | 30/4140 |
| Cardiac failureCardiac disorders | 28/4131 | 17/4157 | 19/4140 | 28/4140 |
| Acute myocardial infarctionCardiac disorders | 23/4131 | 20/4157 | 21/4140 | 28/4140 |
| Coronary artery diseaseCardiac disorders | 22/4131 | 14/4157 | 25/4140 | 24/4140 |
| Angina unstableCardiac disorders | 23/4131 | 22/4157 | 16/4140 | 23/4140 |
| Angina pectorisCardiac disorders | 22/4131 | 19/4157 | 20/4140 | 12/4140 |
| Event | Placebo | Fluticasone Furoate 100 µg | Vilanterol 25 µg | Fluticasone Furoate/Vilanterol 100/25 µg |
|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 969/4131 | 939/4157 | 938/4140 | 779/4140 |
| NasopharyngitisInfections and infestations | 310/4131 | 366/4157 | 352/4140 | 367/4140 |
| HeadacheNervous system disorders | 308/4131 | 332/4157 | 327/4140 | 291/4140 |
| Upper respiratory tract infectionInfections and infestations | 194/4131 | 240/4157 | 212/4140 | 262/4140 |
| CoughRespiratory, thoracic and mediastinal disorders | 254/4131 | 224/4157 | 215/4140 | 206/4140 |
| DyspnoeaNervous system disorders | 172/4131 | 185/4157 | 132/4140 | 125/4140 |
| BronchitisInfections and infestations | 165/4131 | 184/4157 | 168/4140 | 166/4140 |
| Back painMusculoskeletal and connective tissue disorders | 140/4131 | 168/4157 | 162/4140 | 173/4140 |
| HypertensionVascular disorders | 129/4131 | 138/4157 | 124/4140 | 152/4140 |
| InfluenzaInfections and infestations | 118/4131 | 116/4157 | 122/4140 | 137/4140 |
| Age, Continuous(Years) | Placebo | Fluticasone Furoate 100 µg | Vilanterol 25 µg | Fluticasone Furoate/Vilanterol 100/25 µg | Total |
|---|---|---|---|---|---|
| Mean | 65.2 ± 7.90 | 65.0 ± 8.02 | 65.2 ± 7.68 | 65.3 ± 7.97 | 65.2 ± 7.89 |
| Sex: Female, Male(Participants) | Placebo | Fluticasone Furoate 100 µg | Vilanterol 25 µg | Fluticasone Furoate/Vilanterol 100/25 µg | Total |
|---|---|---|---|---|---|
| Female | 1050 | 1098 | 1071 | 1019 | 4238 |
| Male | 3081 | 3059 | 3069 | 3121 | 12330 |
| Race/Ethnicity, Customized(Participants) | Placebo | Fluticasone Furoate 100 µg | Vilanterol 25 µg | Fluticasone Furoate/Vilanterol 100/25 µg | Total |
|---|---|---|---|---|---|
| African American /African Heritage | 61 | 62 | 68 | 69 | 260 |
| American Indian or Alaskan Native | 9 | 5 | 4 | 9 | 27 |
| Asian - Central /South Asian Heritage | 64 | 55 | 62 | 57 | 238 |
| Asian - East Asian Heritage | 192 | 193 | 195 | 192 | 772 |
| Asian - Japanese Heritage | 34 | 36 | 37 | 37 | 144 |
| Asian - Mixed Race | 1 | 0 | 0 | 0 | 1 |
| Asian - South East Asian Heritage | 389 | 399 | 386 | 394 | 1568 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 0 | 2 | 5 |
| White - Arabic/North African Heritage | 14 | 13 | 7 | 12 | 46 |
| White - Mixed Race | 0 | 0 | 0 | 1 | 1 |
| White - White/Caucasian /European Heritage | 3334 | 3367 | 3353 | 3337 | 13391 |
| Mixed Race | 32 | 25 | 28 | 30 | 115 |
Showing the first 100 of 1,621 sites across 44 countries. Choose a country and city above to see the rest.
Ran from Jan 2011 to primary completion in Jul 2015, 53 months.
Results were first posted in Aug 2016, 1 year after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 53 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Vilanterol
Pulmonary Disease, Chronic Obstructive →